Your browser doesn't support javascript.
Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.
Heider, Michael; Grass, Sandra; Dill, Veronika; Rämisch, Stephanie; Winter, Christof; Verbeek, Mareike; Götze, Katharina S; Bassermann, Florian; Jilg, Stefanie.
  • Heider M; Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Germany; Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technical University of Munich, Germany.
  • Grass S; Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Germany.
  • Dill V; Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Germany.
  • Rämisch S; Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Germany.
  • Winter C; Institute of Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Verbeek M; Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Germany.
  • Götze KS; Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), 69120 Heidelberg, Germany.
  • Bassermann F; Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Germany; Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technical University of Munich, Germany; Deutsches Konsortium für Translationale
  • Jilg S; Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Germany. Electronic address: stefanie.jilg@tum.de.
Transfus Apher Sci ; 60(5): 103197, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1275746
ABSTRACT
High-dose chemotherapy followed by autologous stem cell transplantation is a major component in the treatment of patients with multiple myeloma. As a prerequisite, the successful collection of a sufficient number of viable peripheral blood hematopoietic CD34+ cells is critical. A common standard protocol for mobilization is currently not defined and critically discussed especially in German-speaking Europe. In times of the Covid-19 pandemic, safe and effective strategies have to be chosen to minimize hospitalization times and severe courses. In this single-center retrospective analysis, safety and efficacy of cyclophosphamide plus etoposide (CE) and growth-factor support (n = 33) was compared to cyclophosphamide mono treatment and growth-factor support (n = 49) in 82 patients with multiple myeloma at first diagnosis. CE was superior to cyclophosphamide mono with a significantly higher number of collected CD34+ cells (15.46 × 106 CD34+ cells/kg vs. 9.92 × 106 CD34+ cells/kg), significantly faster engraftment of granulocytes after stem cell transplantation (day 10.5 vs. day 11.6), shorter duration of the inpatient stay (17.47 days vs. 19.16 days) and significantly less transfusions (8.82 % vs. 30.61 % patients receiving transfusions). The safety profile was comparable in both groups and in line with published data. We conclude that CE is a safe and highly effective mobilization protocol in patients with multiple myeloma at first diagnosis and appears to be superior to the commonly used cyclophosphamide mono regimen.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematopoietic Stem Cells / Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Mobilization / Cyclophosphamide / Peripheral Blood Stem Cell Transplantation / Etoposide / Multiple Myeloma Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Transfus Apher Sci Journal subject: Hematology Year: 2021 Document Type: Article Affiliation country: J.transci.2021.103197

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematopoietic Stem Cells / Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Mobilization / Cyclophosphamide / Peripheral Blood Stem Cell Transplantation / Etoposide / Multiple Myeloma Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Transfus Apher Sci Journal subject: Hematology Year: 2021 Document Type: Article Affiliation country: J.transci.2021.103197